Abstract:Abstract Background Colonoscopy and polypectomy reduce colorectal cancer incidence and mortality, but is also associated with adverse events, including bleeding. Postpolypectomy delayed bleeding (PPDB) after EMR of large colorectal polyps (≥2cm) has an incidence of 2.6-9.7%. Tranexamic acid is a member of a class of drugs called antifibrinolytic agents. It reduces fibrinolysis by slowing down the conversion of plasminogen to plasmin, which may prevent bleeding. Purpose The goal of this pilot study is to assess the feasibility of using tranexamic acid after EMR of large (≥2 cm) non-pedunculated colorectal polyps (LNPCPs) to prevent PPDB. Method This was a single center feasibility study conducted at the Kingston Health Sciences Center from March 2021 to September 2021. Patients referred for removal of a ≥2cm LNPCP and those who were referred for a positive fecal immunochemical test were approached for consideration of inclusion. Patients with INR ≥ 1.5, platelets <50, higher risk of risk of thromboembolic events (atrial fibrillation on anticoagulation, history of stroke, TIA, pulmonary embolism, deep vein thrombosis hypercoagulable state, mechanical heart valve on anticoagulation, myocardial infarction in the last twelve months), pregnancy or undergoing ESD were not included. Coagulation of submucosal vessels after polypectomy by snare tip coagulation or forceps was performed if thought necessary by the endoscopist. Clipping could be performed only where there was concern for perforation. Intraprocedural bleeding was recorded and managed at the discretion of the endoscopist. After the procedure was completed, 1 gram of TXA in 100mL of normal saline (NS) was infused over a 10-minute interval. The participants received tranexamic acid 1 gram PO TID to be taken for 5 days after the procedure. A post procedure day 5, 14 and 30 phone call was conducted with participants to monitor study drug compliance and adverse events. Result(s) A total of 25 patients were enrolled with a mean polyp size of 3 cm. Baseline patient and polyp characteristics are presented in table 1. 90% of eligible patients approached consented to be in the study. Procedure details are presented in table 2. Intraprocedural bleeding occurred in 7 patients (28%) and all of these were treated with soft coagulation. 2 patients had clipping for muscle injury. All 25 patients received IV TXA post procedure. 16 patients (64%) took every dose of the prescribed pills. 21 patients (84%) took at least 80% of the prescribed TXA pills. 1 patient presented with post polypectomy bleeding. All patients completed the day 30 follow up phone call. There were no adverse events. Image Conclusion(s) TXA to prevent postpolypectomy delayed bleeding (PPDB) was feasible to use with no adverse events reported. All patients received IV TXA post procedure and completed 30 day follow up. However, only 64% of patients took every scheduled dose of medication. A randomized controlled study will be needed to see if TXA can significantly reduce PPDB. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Queen's University DOM Research Award – Clinical Innovation Disclosure of Interest None Declared

S297 Navigating Antithrombotic Medication Management for Colonoscopy: Patient Perspectives

Clinicians' Adherence And Patients' Compliance To Guidelines For The Management Of Antithrombotics In Patients Undergoing Colonoscopic Polypectomy

CLINICIAN INSTRUCTIONS ON MANAGEMENT OF ANTITHROMBOTICS BEFORE COLONOSCOPY: A RETROSPECTIVE ANALYSIS OF 4,777 PATIENTS IN ONE YEAR COHORT

Impact of Physicians’ and Patients’ Compliance on Outcomes of Colonoscopic Polypectomy With Anti-Thrombotic Therapy

Interruption Of Anti-Thrombotic Therapies And Risk Of Post-Colonoscopy Thromboembolic Events: A Real-World Cohort Study

Risks of bleeding and thromboembolic events in patients undergoing colonoscopy on uninterrupted and interrupted anticoagulant therapy in real-world setting

Prevention of Gastrointestinal Events in Patients on Antithrombotic Therapy in the Peri‐endoscopy Period: Review of New Evidence and Recommendations from Recent Guidelines

Managing anticoagulation and antiplatelet medications in GI endoscopy: a survey comparing the East and the West

A109 TRANEXAMIC ACID TO PREVENT BLEEDING AFTER ENDOSCOPIC RESECTION OF LARGE COLORECTAL POLYPS: A PILOT PROJECT

Su1636 Risk of Post Colonoscopic Polypectomy Bleeding in Patients on New Oral Anti-Coagulant and a Case Control Study

Management of Patients with Breast Biopsy under Anti-Coagulation or Anti-Platelet Therapy: Results of a Survey of German Experts

Risk of Postpolypectomy Bleeding with Uninterrupted Clopidogrel Therapy in an Industry-Independent, Double-Blind, Randomized Trial.

Periprocedural Edoxaban Management and Clinical Outcomes in Patients Undergoing Transcatheter Cardiovascular Procedures in the EMIT-AF/VTE Program

Patient's Perceptions of Importance of Discontinuing Antithrombotic Medication Before Oculoplastics Surgery

Medical Clinics of North America-Periprocedural Antithrombotics: Prophylaxis and Interruption

Feasibility and acceptability of patient- and clinician-level antithrombotic stewardship interventions to reduce gastrointestinal bleeding risk in patients using warfarin (Anticoagulation with Enhanced Gastrointestinal Safety): a factorial randomized controlled pilot trial

Questionnaire-Based Survey on Gastrointestinal Bleeding and Management of Antithrombotic Agents During Endoscopy among Asian Countries.

Pharmacotherapeutic prophylaxis and post-operative outcomes within an Enhanced Recovery After Surgery (ERAS®) program: A randomized retrospective cohort study

Antithrombotic management in patients with percutaneous coronary intervention requiring oral anticoagulation

Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review

Patient Perspectives on Factors Affecting Direct Oral Anticoagulant Use for Stroke Prevention in Atrial Fibrillation